Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ready To Launch But Nowhere To Go: Regeneron’s Eylea Delayed

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Regeneron Pharmaceuticals Inc. has a sales team in place and is ready to launch its biologic Eylea (aflibercept) for neovascular age-related macular degeneration, but the launch will have to wait now that FDA extended the PDUFA date for the vascular endothelial growth factor inhibitor by three months to Nov. 18.

You may also be interested in...



Drug/Device Combinations: New Position Paper Explains Notified Body Responsibilities

Medicinal products authorities will consider a medtech notified body opinion on the device element of a drug/device combination product. A new position paper explains how roles and responsibilities are shared between medtech and medicinal product experts.

GC Pharma Aiming To Outrun Rivals For COVID-19 Plasma Therapy

A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.

QUOTED. 9 April 2020. Frans van Houten.

Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.

Topics

UsernamePublicRestriction

Register

PS004817

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel